New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.

[1]  A. Halabi,et al.  Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment , 2022, Scientific Reports.

[2]  P. Gosse,et al.  Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial , 2022, The Lancet.

[3]  Ji-Guang Wang,et al.  Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan , 2022, Journal of clinical hypertension.

[4]  Emily K. McCoy,et al.  Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension , 2021, Journal of cardiovascular pharmacology.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, Systematic Reviews.

[6]  M. Fontes,et al.  Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects , 2020, Clinical pharmacology in drug development.

[7]  M. Burnier,et al.  Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet , 2020, Clinical pharmacology and therapeutics.

[8]  J. Dingemanse,et al.  Effects of Multiple‐Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin , 2020, Clinical pharmacology in drug development.

[9]  J. Ménard,et al.  Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension , 2020, Hypertension.

[10]  J. Dingemanse,et al.  Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment , 2019, Clinical Drug Investigation.

[11]  J. Dingemanse,et al.  Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects , 2019, Drug design, development and therapy.

[12]  D. Webb,et al.  Endothelins in cardiovascular biology and therapeutics , 2019, Nature Reviews Cardiology.

[13]  J. Ménard,et al.  Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[14]  M. Iglarz,et al.  Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[15]  Jun Pu,et al.  Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta‐Analysis of 4894 Patients From 24 Randomized Double‐Blind Placebo‐Controlled Clinical Trials , 2016, Journal of the American Heart Association.

[16]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[17]  C. Southan,et al.  Endothelin , 2016, Pharmacological Reviews.

[18]  E. Boesen.  Endothelin receptors, renal effects and blood pressure. , 2015, Current opinion in pharmacology.

[19]  L. Ruilope,et al.  Avosentan for overt diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[20]  D. Sommerfeld,et al.  Clinical approach in treatment of resistant hypertension , 2009, Integrated blood pressure control.

[21]  M. Burnier,et al.  Dose‐Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects , 2009, Clinical pharmacology and therapeutics.

[22]  S. Oparil,et al.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. , 2008, Archives of internal medicine.

[23]  M. Ratain,et al.  Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies , 2004, Clinical Cancer Research.

[24]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[25]  M. Nicholls,et al.  Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. , 2000, The American journal of cardiology.

[26]  S. Kira,et al.  Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. , 1995, The American journal of physiology.

[27]  A. Davenport,et al.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub‐type , 1995, British journal of pharmacology.

[28]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[29]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.